2mg vial
Tesamorelin is a stabilised 44-amino-acid GHRH analogue, FDA-approved as Egrifta for HIV-associated lipodystrophy. It produces a robust GHRH-driven GH/IGF-1 pulse and is the most clinically validated GHRH analogue for visceral adipose tissue (VAT) reduction without compromising subcutaneous fat or lean mass.
Checking availability…
Binds pituitary GHRH receptors to stimulate endogenous GH synthesis and release, with downstream IGF-1 elevation. N-terminal modification protects against DPP-4 degradation, extending half-life vs native GHRH.
Standard research/clinical protocols use 1–2mg subcutaneously once daily, typically pre-sleep. Cycles typically run 12–26 weeks with reassessment. Often stacked with a GHRP (e.g. Ipamorelin) for amplified pulse synergy.
approx. 25–40 minutes plasma; functional GH/IGF-1 elevation persists 12–24 hours.
Reconstitute a 5mg vial with 1–2mL bacteriostatic water for a 2.5–5mg/mL working concentration. Swirl gently - do not shake.
Lyophilised: 2–8°C, stable 24 months. Reconstituted: 2–8°C, use within 14–28 days depending on diluent.